{"prompt": "['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'are not limited to, uncontrolled ventricular arrhythmia, history of prior myocardial', 'infarction, uncontrolled major seizure disorder, uncontrolled hypertension (BP \"160/100),', 'history of prior stroke, uncontrolled diabetes (hgb A1C>7) unstable spinal cord', 'compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on', 'High Resolution Computed Tomography (HRCT) scan or any psychiatric disorder that', 'prohibits obtaining informed consent.', '15. Patients unable to swallow orally administered medication and patients with', 'gastrointestinal disorders likely to interfere with absorption of the study medication.', '16. Immunocompromised patients, e.g., patients who are known to be serologically positive', 'for human immunodeficiency virus (HIV).', '17. Patients with a known hypersensitivity to olaparib or any of the excipients of the product.', '18. Patients with a known hypersensitivity to the testosterone cypionate or any of the', 'excipients of the product', '19. Patients with known active hepatitis (i.e., Hepatitis B or C) due to risk of transmitting the', 'infection through blood or other body fluids', '20. Previous allogenic bone marrow transplant or double umbilical cord blood transplantation', '(dUCBT)', '21. Whole blood transfusions in the last 120 days prior to entry to the study (packed red blood', 'cells and platelet transfusions are acceptable, for timing refer to inclusion criteria no. 10)', '22. Evidence of serious and/or unstable pre-existing medical, psychiatric or other condition', '(including laboratory abnormalities) that could interfere with patient safety or provision of', 'informed consent to participate in this study.', '23. Any psychological, familial, sociological, or geographical condition that could potentially', 'interfere with compliance with the study protocol and follow-up schedule.', '24. Evidence of disease that, in the opinion of the investigator, would put the patient at risk', 'from testosterone therapy (e.g. femoral metastases with concern over fracture risk, spinal', 'metastases with concern over spinal cord compression, lymph node disease with concern', 'for ureteral obstruction).', '25. Patients with pain attributable to their prostate cancer', '26. Tumor causing urinary outlet obstruction that requires catheterization for voiding. Patients', 'that require catheterization to void secondary to benign strictures or other non-cancer', 'causes will be permitted to enroll.', '27. Prior history of deep venous thrombosis or pulmonary embolism within 5 years prior to', 'enrollment in the study and not currently on systemic anticoagulation.', '35(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', '28. Patients with NYHA (New York Heart Association) class III or IV heart failure or history', 'of a prior myocardial infarction (MI) prior to enrollment in the study.', '4.', 'STUDY PLAN AND PROCEDURES', '4.1', 'Overall study design and flow chart', 'This will be a single arm, Phase II study designed to evaluate the clinical activity of bipolar', 'androgen therapy (BAT) plus olaparib in patients with asymptomatic metastatic castration-', 'resistant prostate cancer (mCRPC) (i.e. progressive prostate cancer in spite of serum', 'testosterone <50 ng/dL) that has already progressed on abiraterone and/or enzalutamide', '(Figure 11). While DNA damage repair (DDR) deficiency is not required to be eligible for the', 'study, all patients must have next-generation sequencing performed at baseline to assess DDR', 'status. The study will require that 50% of enrolled subjects have homozygous deletions,', 'deleterious mutations, or both in one or more of the DDR genes listed in Appendix 5. The', 'other 50% of patients must have an intact DDR pathway (i.e. no mutations/deletions in genes', 'listed in Appendix 5).', 'All patients will continue on androgen deprivation therapy (ADT) (i.e. surgical or medical', 'castration), and should have a two-week washout from their most recent mCRPC therapy and', 'weaned from steroids prior to enrollment. Eligible patients will initiate T enanthate or T', 'cypionate 400 mg intramuscular every 28 days, which has been shown to result in rapid', 'fluctuations between supraphysiologic and near castrate serum T levels in men maintained on', 'ADT [11]. Patients will also receive olaparib 300 mg by mouth twice daily. One treatment', 'cycle will be defined as 28-days, and consist of 1 dose of T enanthate or T cypionate on Day 1', 'combined with continuous daily dosing of olaparib (Days 1-28).', 'PSA will be measured on Day 1 of each treatment cycle prior to receiving T enanthate or T', 'cypionate. Radiographic assessment with bone and CT scans will occur every 12-weeks. The', 'primary endpoint will be PSA after 3-cycles of BAT plus olaparib (i.e. 12-weeks). Patients', 'will be permitted to continue until disease progression by radiographic (per RECIST 1.1 or', 'PCWG3) or clinical criteria (e.g. increasing pain), whichever comes first [95, 96]. Prior to', 'completing 3-cycles of treatment, patients should not discontinue treatment for PSA', 'progression alone; however, if after 3-cycles the PSA has not decreased 50% from baseline', '(i.e. PSA50 response) that patient may withdraw from the study if their treating physician feels', 'it is in their best interest. It is also essential that PSA be measured before injection of', 'Testosterone given that some patients may experience a transient increase in PSA immediately', 'following T dosing. PSA values obtained at timepoints other than those required per protocol', 'will be ignored and not used for the purpose of determining disease progression.', 'Blood and tumor tissue for secondary analyses and correlative studies will be collected.', 'Metastatic biopsies will be obtained at baseline, on Day 8 of Cycle 1 and again upon', 'progression when possible. This tissue will be used for molecular studies and to measure', 'intratumoral androgen levels. Blood for molecular studies will be collected serially at', '36(93)', 'Printed on 3/25/202']\n\n###\n\n", "completion": "END"}